InterbrandHealth Releases 2016 Best Pharma Brands Report
A global study by InterbrandHealth identifies the top biopharma companies that are addressing the needs of healthcare professionals, payers, and policymakers. These companies are ranked by “qualifying the industry’s definition of value through brand, then quantifying the corporate brand’s contribution to business performance.” Below are the 10 most valuable biopharma brands.
1. Pfizer (USD $19.985 billion)
2. Roche Group (USD $15.479 billion)
3. Merck & Co., Inc., Kenilworth, N.J., U.S.A. (USD $13.880 billion) [Note: MSD outside of the United States & Canada]
4. Janssen: Pharmaceutical Companies of Johnson & Johnson (USD $13.866 billion)
5. Novartis (USD $13.496 billion)
6. Amgen (USD $13.461 billion)
7. Gilead Sciences (USD $13.361 billion)
8. Novo Nordisk (USD $10.206 billion)
9. AstraZeneca (USD $8.123 billion)
10. GSK (USD $6.778 billion)
